An incredible 17,000 volunteers recruited in just 17 months!

October 2003

Richmond Pharmacology has an exceptional volunteer database of over 17,000 volunteers and continues to outshine the competition, recruiting on average 1,000 new volunteers each month.

Richmond has far surpassed other CROs, which take many years to build a similarly substantial database of potential volunteers. Richmonds unparalleled and proactive recruitment strategy has taken just 17 months to achieve an outstanding 17,000 volunteers on the database.Richmonds huge success with volunteer recruitment speaks for itself, having started eight new studies on time, during August this year, which included a record 158 volunteers! This demonstrates the efficiency of Richmonds process and the dedication of its staff.The substantial database also holds a wide range of patient populations which ensures that Richmonds first-rate recruitment team continue to meet all recruitment targets – particularly those for special populations – while offering a standard of service unmatched by competitors – providing clients with an efficient, superior trial with quality driven results.Richmond Pharmacology has – according to third parties – by far the largest dedicated volunteer recruitment department of any Phase 1 CRO in the UK, meaning delivery of volunteer numbers is guaranteed within the quoted budget, at no extra cost to the clients.Richmond Pharmacology’s recruitment website, is designed for volunteers and includes specific information, frequently asked questions and online registration.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more